Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus local minimally invasive therapy for primary liver cancer
ChiCTR-TRC-13004547Phase 4Completed
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Overall survival and Time to progression. Started Apr 2014; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13004547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004547.